Lepu Medical's immuno-oncology spinoff secured $186m in a round co-led by Ping An Capital and the Sunshine Insurance-backed Riverhead Capital.
Ping An Capital, a corporate venturing subsidiary of insurance group Ping An, has co-led a RMB1.29bn ($186m) series B round for China-based oncology therapy developer Lepu Biotech, DealStreetAsia reported today.
The round was co-led by Riverhead Capital, a private equity firm backed by insurance firm Sunshine Insurance, and included Haitong Securities, the state-owned SDIC Unity Capital and a joint fund for Qingdao Minxin Qiyuan Investment and China Reform Holdings.
Formed as a subsidiary of medical technology manufacturer Lepu Medical, Lepu…
